🆕New research published in our Special Collection on Autoimmune Neurology and Paraneoplastic Neurologic Syndromes:

📊Efficacy, safety, and immunological effects of #efgartigimod in patients with Guillain–Barré syndrome
journals.sagepub.com/doi/full/10....

Early Efgartigimod Juvenile MG Trial Results: Safety, Efficacy Similar in Adolescents and Adults Phase 2/3 ADAPT JR interim results suggest efgartigimod is safe and active in adolescents with AChR-positive juvenile MG.

#MDAConference: Interim results from the ADAPT JR trial demonstrate that intravenous #Efgartigimod is safe, well tolerated, and pharmacodynamically active in adolescents with #AChR antibody-positive generalized #MyastheniaGravis (MG). @mda.org

Read more: https://bit.ly/4rh8dzp

Early Efgartigimod Juvenile MG Trial Results: Safety, Efficacy Similar in Adolescents and Adults Phase 2/3 ADAPT JR interim results suggest efgartigimod is safe and active in adolescents with AChR-positive juvenile MG.

Interim results from the #ADAPT JR trial demonstrate that intravenous #Efgartigimod is safe, well tolerated, and pharmacodynamically active in adolescents with #AChR antibody-positive generalized myasthenia gravis (#MG). @mda.org #MDAConference

Read more: https://bit.ly/4bbT4cE

#MyastheniaGravis

We're proud to support and publish #AccessibleResearch!

This Plain Language Summary of a Publication (#PLSP) covers the ADHERE clinical study on #efgartigimod in CIDP in an accessible form.
We hope you enjoy the informative, easy-to-understand infographics: journals.sagepub.com/doi/epdf/10....

Preoperative Efgartigimod May Help Stabilize Patients With MG After Thymectomy Preoperative treatment with efgartigimod may help stabilize patients with myasthenia gravis and improve outcomes after thymectomy.

Treatment with #Efgartigimod prior to #Thymectomy may provide greater improvements in functional scores and antibody titers in patients with #MyastheniaGravis (MG). Study in Acta Neurologica Scandinavica.

Read more: https://bit.ly/4ovIlOW

#RareDisease #Neurology

Autoantibody targeting therapies in post COVID syndrome and myalgic encephalomyelitis/chronic fatigue syndrome Published in Expert Opinion on Biological Therapy (Vol. 25, No. 5, 2025)

Gute Übersicht zum aktuellen Forschungsstand (04/2025) von Autoantikörper-gerichteten Therapien bei #LongCovid & #MECFS

Vergleich aktueller Erkenntnisse zu #Rituximab, #Efgartigimod, #Daratumumab, #Immunadsorption, #BC007 & #IVIG

Die Tabelle im Link bietet eine schnelle Übersicht der Ergebnisse.

Efgartigimod: Hoffnung für CIDP-Patienten? Die Therapieoptionen für Patienten mit chronischer inflammatorischer demyelinisierender Polyradikuloneuropathie sind begrenzt. Ist ein Wirkstoff aus der Myasthenie-Behandlung die Lösung?

Wann endlich eine große #Efgartigimod Studie für #severeME?

Ach ne, #MEcfs ist ja die Krankheit, um die alle einen Bogen machen.
Für die es kein Geld gibt.
Wo die @dgn-ev.bsky.social Sekte Forschung verhindern will.
Dann halt nicht.

#severeMEAwarenessDay

www.doccheck.com/de/detail/ar...

Argenx presents new efgartigimod data at EULAR 2025 - PharmaTimes Rheumatology studies show promising results for Sjogren’s disease

#pharmaceuticals #Rheumatology #NeuromuscularDisease #Argenx #efgartigimod #efgartigimoddata #EULAR2025 #Sjogrensdisease #myositis #FastTrackdesignation #primarySjogrensdisease #ALKIVIAstudy #myositispatients #FcRninhibitor #UNITYtrial
pharmatimes.com/news/argenx-...

The Future of Idiopathic Inflammatory Myositis: Market Insights and Emerging Therapies through 2034 The idiopathic inflammatory myositis market is projected to achieve remarkable growth due to emerging therapies and increasing prevalence of the disease.

The Future of Idiopathic Inflammatory Myositis: Market Insights and Emerging Therapies through 2034 #None #Myositis #Dazukibart #Efgartigimod

PC-POTS Update Results from the Phase 2 ALPHA study of efgartigimod in post-COVID-19-mediated postural orthostatic tachycardia syndrome (PC-POTS) show that treated patients had no clinically meaningful improvement compared to placebo on the total Malmo POTS symptom (MaPS) score and COMPASS31. The observed safety and tolerability profile of efgartigimod in the ALPHA study was consistent with previous clinical trials. argenx will not move forward with development in PC-POTS and plans to prioritize resources to the nearly 50 active clinical trials in its expanding pipeline.

Argenx just issued a press release in which it says that the company will not advance development of #Efgartigimod in #LongCOVID / #PostCOVID - #POTS based on Phase 2 ALPHA data.

www.argenx.com/news/argenx-...